TTR and neuropathy: Eplontersen is a novel ASO formulation that reduced serum TTR, lessened neuropathy impairment, and improved quality of life compared to a historical placebo in ATTRv polyneuropathy patients in the phase 3 NEURO‐TTRansform trial.72